Genfit has a number of on-going R&D programmes across multiple indications of global cardiometabolic risk. These programmes represent advanced research using a multimodal approach, which aims to treat and prevent a number of risk factors such as dyslipidemia, diabetes, obesity and atherosclerosis simultaneously.

  • What is Cardiometabolic Disease?

Cardiometabolic disease is a multifactoral epidemic, representing the leading cause of mortality worldwide and a major international health issue.

  • Genfit's Multimodal Approach

Genfit's multimodal approach is an innovative strategy to develop drugs with a single active ingredient to treat several risk factors simultaneously.

  • Genfit's Advanced Compound Status

Genfit has several compounds in clinical development: Learn more about the therapeutic positioning and development status of our most advanced drug development programmes.